Table 2.
Primary immune thrombocytopenia (ITP) following essential thrombocythemia (ET), Bone marrow (BM) biopsy, dexamethasone (DXM) 40 mg/day × 4 days, intravenous immunoglobulin (IVIG), ANA (anagrelide), HU (hydroxyurea), prednisone (PD), MPD: methylprednisolone, azathioprine (AZT), and acetylsalicylic acid (ASA).
| Authors | [6] | [7] | [8] |
|---|---|---|---|
| No | 1 | 2 | 3 |
| Gender | Female | Male | Female |
| ET diagnosis | 2014 | 2018 | March 2001 |
| Mutation | JAK2V617 | JAK2V617 (53% allele burden) | JAK2V617 |
| BM biopsy | Compatible with ET | Compatible with ET | Compatible with ET |
| ET treatment | HU | (1). HU (2). ASA |
(1). ASA (2). ANA—switching to HU due to intolerance |
| ITP diagnosis | 70-year-old (2019) |
95-year-old (April 2018) |
42-year-old (October 2001) |
| Interval between diagnosis of ITP after ET | 5 years (5 months after introduction of HU) | Few weeks | 7 months |
| ITP treatment | (1): PD + IVIg | (1) MPD i.v. (2) PD |
(1) DXM |
| Additional notes | Anti-Helicobacter pylori antibody test was positive | Diagnosis of TTP in 1994 (treated with plasmapheresis and vincristine) |